The relevance of finding biomarkers to identify the best candidates for nucleos(t)ide analogue discontinuation in HBeAg-negative chronic hepatitis B [0.03%]
寻找停用恩替卡韦治疗的慢性乙肝患者复发风险生物标志物的意义
Sabela Lens,Sofía Pérez Del Pulgar,Xavier Forns
Sabela Lens
Associations between per- and polyfluoroalkyl substances and adolescent non-alcoholic fatty liver disease [0.03%]
全氟和多氟烷基物质与青少年非酒精性脂肪肝的关系
Longgang Zhao,Xinyuan Zhang,Alan Ducatman et al.
Longgang Zhao et al.
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial [0.03%]
叶酸改善肝硬化患者普萘洛尔降低门脉压力的作用：一项随机安慰剂对照试验
Ranka Vukotic,Roberto Di Donato,Greta Roncarati et al.
Ranka Vukotic et al.
Background & aims: β-blockers reduce hepatic venous pressure gradient (HVPG) by decreasing portal inflow, with no reduction in intrahepatic vascular resistance. 5-Methyltetrahydrofolate (5-MTHF) can prevent oxidative los...
Randomized Controlled Trial
Journal of hepatology. 2023 Oct;79(4):977-988. DOI:10.1016/j.jhep.2023.06.017 2023
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial [0.03%]
givosiran治疗急性间歇性肝卟啉病的疗效和安全性：随机III期ENVISION试验最终结果
David J Kuter,Herbert L Bonkovsky,Susana Monroy et al.
David J Kuter et al.
Background & aims: Acute hepatic porphyria (AHP) is caused by defects in hepatic heme biosynthesis, leading to disabling acute neurovisceral attacks and chronic symptoms. In ENVISION (NCT03338816), givosiran treatment for...
The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma [0.03%]
XOR-IDH3α轴调控肝细胞癌中的巨噬细胞极化作用
Yijun Lu,Qikai Sun,Qifei Guan et al.
Yijun Lu et al.
Background & aims: Tumor-associated macrophages (TAMs) are indispensable in the hepatocellular carcinoma (HCC) tumor microenvironment. Xanthine oxidoreductase (XOR), also known as xanthine dehydrogenase (XDH), participate...
Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2 [0.03%]
微调microRNA-145a-5p通过上调Nr4a2促进脂肪变性向NASH进展
Bo Li,Ziyi Yang,Fei Mao et al.
Bo Li et al.
Background & aims: The molecular mechanisms underlying the progression of simple steatosis to non-alcoholic steatohepatitis (NASH) remain incompletely understood, though the potential role of epigenetic regulation by micr...
Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma [0.03%]
假长双歧杆菌生成的乙酸可抑制非酒精性脂肪肝病相关肝细胞癌
Qian Song,Xiang Zhang,Weixin Liu et al.
Qian Song et al.
Background & aims: Recent studies have highlighted the role of the gut microbiota and their metabolites in non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC). We aimed to identify specific b...
Treating NASH by targeting peroxisome proliferator-activated receptors [0.03%]
通过靶向过氧化物酶体增殖激活受体治疗NASH
Bart Staels,Laura Butruille,Sven Francque
Bart Staels
The pathophysiology of non-alcoholic steatohepatitis (NASH) encompasses a complex set of intra- and extrahepatic driving mechanisms, involving numerous metabolic, inflammatory, vascular and fibrogenic pathways. The peroxisome proliferator-a...
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice [0.03%]
强效广谱中和抗体VIR-3434可控制人源化小鼠的乙型肝炎和丁型肝炎病毒感染并降低HBsAg水平
Florian A Lempp,Tassilo Volz,Elisabetta Cameroni et al.
Florian A Lempp et al.
Background & aims: Chronic hepatitis B is a global public health problem, and coinfection with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a hepatitis B virus (HBV) surface antigen (HBsAg)-targe...
Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis [0.03%]
siRNA靶向N6-甲基腺苷阅读蛋白YTHDF1通过抑制EZH2-IL-6轴增强非酒精性脂肪肝相关肝癌的抗肿瘤免疫反应
Lina Wang,Lefan Zhu,Cong Liang et al.
Lina Wang et al.
Background & aims: RNA N6-methyladenosine (m6A) reader protein YTHDF1 has been implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non-alcoholic steatohepatitis-associated HCC (NASH-HC...